Cite
HARVARD Citation
You, B. et al. (2022). Identification of Patients With Ovarian Cancer Experiencing the Highest Benefit From Bevacizumab in the First-Line Setting on the Basis of Their Tumor-Intrinsic Chemosensitivity (KELIM): The GOG-0218 Validation Study. Journal of clinical oncology. 40 (34), pp. 3965-3974. [Online].